Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a | Zendy

Rania M. El-Lababidi | Zendy; Mohamad Mooty | Zendy; Maria-Fernanda Bonilla | Zendy; Nouran Salem | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Treatment of severe pneumonia due to COVID-19 with peginterferon alfa 2a

Author(s) -

Rania M. El-Lababidi,

Mohamad Mooty,

Maria-Fernanda Bonilla,

Nouran Salem

Publication year - 2020

Publication title -

idcases

Language(s) - English

Resource type - Journals

ISSN - 2214-2509

DOI - 10.1016/j.idcr.2020.e00837

Subject(s) - medicine , covid-19 , pneumonia , outbreak , coronavirus , virology , atypical pneumonia , betacoronavirus , intensive care medicine , disease , infectious disease (medical specialty)

The outbreak of the new coronavirus disease 2019 (COVID-19) has spread rapidly worldwide. Until now, no definite effective treatment has been identified. We reported 3 patients with severe COVID-19 treated with pegylated interferon alfa 2a with satisfactory recovery. Based on these observations, randomized studies with interferons should be considered in deteriorating patients infected with COVID-19.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research